Multilayered control of retinal stem/progenitor cell fate in the single-cell and organoid era: Developmental blueprints and regenerative opportunities

Table 1 Retinal regenerative lineage library - comparative controllability, scalability, and translational fit

Lineage/source class	Representative product/strategy in manuscript	Primary strengths	Dominant controllability limits	Key safety risks	Best-fit indication stage	Translational role in your framework
Embryonic/developmental RPCs	“Reference progenitors” defining competence windows	Gold-standard developmental program; informs TF/enhancer logic	Not scalable; not a clinical source	Ethical/availability constraints	N/A (instructional)	Blueprint to recreate/bypass competence windows
MG in situ	In vivo reprogramming	Anatomically native; correct laminar position	Competence locked by Notch/NFI/Prox1; prone to reactive reversion	Off-target AAV expression; scarring; uncontrolled proliferation	Early-intermediate, niche-permissive	“Gene-only” regeneration if evidence-standard met
CMZ-like/adult stem cell candidates	Hypothesis-generating reservoirs	May reveal edge-niche triggers	In vivo neurogenesis inconsistent; culture-induced artifacts	Lineage ambiguity	Low priority	Mechanistic inspiration rather than a product source
hPSC-RPE (suspension)	Subretinal injection; RPESC-RPE-4W	Mature monolayer identity; imaging-friendly endpoints	Repolarization on diseased Bruch’s; heterogeneous distribution	Proliferation/tumorigenicity monitoring needed	Intermediate-advanced GA/AMD	Clinically advanced “vanguard” replacement
hPSC-RPE (patch/scaffold)	CPCB-RPE1, sheets/patches	Pre-polarized monolayer; surrogate substrate	Higher surgical burden; complication spectrum	PVR/retinal detachment risk	Advanced structural loss	Durability-first strategy
Photoreceptor precursors	“Goldilocks zone” post-mitotic precursors	Potential for vision restoration via synaptic integration	Integration vs material transfer confound; maturity tuning required	Ectopic differentiation; limited connectivity proof	End-stage vs mid-stage stratification needed	Replace + require rigorous mechanism-of-benefit parsing
Organoid-derived laminated outputs	Engineered scaffolds; ecosystem completion	Tissue-like architecture; testbed for causality + product	Heterogeneity, batch effects; microenvironment missingness	Off-target tissues; stress programs	Preclinical → translational	Programmable developmental proxy + manufacturing challenge

RPCs: Retinal progenitor cells; TF: Transcription factor; N/A: Not applicable; MG: Müller glia; NFI: Nuclear factor I; Prox1: Prospero homeobox 1; AAV: Adeno-associated virus; CMZ: Ciliary marginal zone; hPSC-RPE: Human pluripotent stem cell-derived retinal pigment epithelium; RPESC: Retinal pigment epithelium stem cell; RPESC-RPE-4W: Retinal pigment epithelium stem cell-derived retinal pigment epithelium progeny at 4 weeks of differentiation; GA: Geographic atrophy; AMD: Age-related macular degeneration; CPCB-RPE1: California Project to Cure Blindness-retinal pigment epithelium 1; PVR: Proliferative vitreoretinopathy; RPE: Retinal pigment epithelium.

Table 2 Atlas-to-engineering toolkit - multi-omics reference types, inference outputs, and what they enable experimentally

Reference/method class	What it quantifies (output)	“Control objects” you can engineer	Best validation experiment	Key pitfalls you should flag in text
scRNA/snRNA atlases	Cell states; trajectories; GRNs	TF modules; lineage branch points	Perturb TFs; scRNA readout + reference mapping	Marker mimicry; stress-induced pseudo-states
Multiome (RNA + ATAC)	State + chromatin accessibility	Competence windows; enhancer permission space	Time-gated TF pulses aligned to accessibility shifts	Accessibility ≠ activity; batch effects
3D genome/enhancer-promoter maps	Regulatory architecture	Cis-regulatory nodes; enhancer hubs	dCas9 recruitment/CRISPRi to specific enhancers	Context dependence; cell-type specificity required
Spatial multi-omics	Niche-positioned states	Layer-aware targets; microenvironment coupling	Perturb niche cues + spatial readouts	Resolution limits; deconvolution artifacts
CellRank/fate probability	Decision regions; fate bias	“Threshold tuning” at branchpoints	Perturb node then compare fate probabilities	Velocity assumptions; sampling density
CellChat/LR inference	Niche signaling network	Immune/niche gating; permissive vs restrictive cues	Ligand blockade/receptor editing + readouts	LR inference is probabilistic, not causal
Cross-species mapping	Conserved vs divergent programs	Identify why mammalian competence is lost	Match intervention nodes across species	Orthology mismatch; latent space alignment bias
Reference mapping benchmarks	Congruence to fetal tissue	Quantitative maturity score	Iterative differentiation optimization loop	Overfitting to reference; missing rare subtypes

scRNA: Single-cell RNA; snRNA: Single-nucleus RNA; GRNs: Gene regulatory networks; TF: Transcription factor; ATAC: Assay for transposase-accessible chromatin; 3D: Three-dimensional; dCas9: Catalytically dead Cas9; CRISPRi: CRISPR interference; LR: Ligand-receptor.

Table 3 Müller glia reprogramming “minimal experimental standard” - non-negotiable evidence hierarchy for conversion claims

Evidence tier	What must be demonstrated	Minimum required controls	Readouts that count as “orthogonal”	Pass/fail interpretation rule	Typical artifact this prevents
Tier 1: Genetic lineage tracing	Converted neurons are MG-origin	MG-specific inducible CreERT2; quantify recombination efficiency	Reporter-independent validation	No tracing = claim not interpretable	Mis-assigned cellular origin
Tier 2: Vector specificity/promoter leakage control	Transgene expression is cell-type restricted	AAV-GFAP leakage tests; alternative promoters; no-virus controls	Spatial mapping of transgene vs cell identity	Leakage unresolved = conversion invalid	“Apparent conversion”
Tier 3: Single-cell identity triangulation	True fate switch vs stress mimicry	Injury-only vs intervention; batch controls	scRNA ± ATAC; stress signatures; GRN congruence	Marker-only = insufficient	Stress-induced pseudo-neurons
Tier 4: Morphology + protein-level confirmation	Neuronal morphology consistent	Blinded morphometrics; layer localization	Immunostaining + morphology metrics	Partial markers without morphology = weak	Marker contamination
Tier 5 Physiology + circuit-level function	Functional maturation & integration	Electrophysiology controls; synapse evidence	Patch clamp; stimulus responses; connectivity proxies	No function = not therapeutic	Immature “neuron-like” cells
Tier 6: Contextual reproducibility	Robust across injury paradigms	Excitotoxic vs mechanical injury	Same validation stack across models	Single-context only = fragile	Context-dependent artifacts

MG: Müller glia; CreERT2: Cre recombinase-estrogen receptor T2 fusion protein; AAV: Adeno-associated virus; GFAP: Glial fibrillary acidic protein; scRNA: Single-cell RNA; ATAC: Assay for transposase-accessible chromatin; GRN: Gene regulatory network.

Table 4 “Minimal controllable node set” as an operational scaffold for more reproducible, mechanism-anchored fate engineering - modules, targets, tools, and success metrics

Module	Engineering objective	Representative control nodes mentioned	Implementable tools (examples you already cite)	Timing logic	Primary success metrics	Typical failure modes
TF intent	Specify lineage/subtype + maturation	Combinatorial TF designs; staged programming	AAV timed expression; programmable delivery platforms	Competence induction → commitment → maturation	Fate fraction + subtype markers + functional readiness	Single-factor insufficiency; wrong temporal window
Epigenetic permission	Open required enhancer repertoire	Enhancer priming; cis-regulatory logic; 3D genome nodes	dCas9-based recruitment/CRISPRi; enhancer-first interventions	Must precede/overlap TF pulses	ATAC congruence; motif availability; reference-mapped maturity	Global de-repression; non-specific dedifferentiation
Microenvironment calibration	Prevent reversion; support integration	NF-κB; monocyte infiltration (CCR2+); metabolic/ECM/oxygen tuning	Immune phase control; niche editing; metabolic conditioning	Permissive inflammation early → resolution late	Stability over time; reduced gliosis; integration-level readouts	Reactive reversion; inflammatory bottleneck; stress collapse

TF: Transcription factor; AAV: Adeno-associated virus; 3D: Three-dimensional; dCas9: Catalytically dead Cas9; CRISPRi: CRISPR interference; ATAC: Assay for transposase-accessible chromatin; NF-κB: Nuclear factor kappa B; CCR2+: C-C chemokine receptor type 2-positive; ECM: Extracellular matrix.

Table 5 Clinical pathway + endpoint stack + chemistry, manufacturing, and controls interface for cell-replacement therapy

Clinical modality	Delivery plane/format	Biological trade-off	Recommended endpoint stack (early phase)	CMC release criteria anchor (identity/purity/potency)	Major confounders to control	Evidence level framing in your text
RPE - cell suspension	Subretinal injection	Scalable + simpler surgery; risks non-uniform monolayer	OCT graft coverage; FAF atrophy expansion; microperimetry/dark adaptation	Identity: Polarity markers; purity: Residual pluripotency; potency: Phagocytosis + TEER	Bruch’s membrane integrity; atrophic niche variability	Level II-III feasibility; signals not definitive
RPE - patch/scaffold	Sheet/patch implant	Pre-polarized monolayer; higher surgical complexity	Same stack + implant positioning stability	Same axes + mechanical integrity (implant)	PVR/retinal detachment; immune response modulation by scaffold	Durability-oriented but complication-prone
RPE - strip (hybrid)	“Strip” transplantation	Balances handling vs structure	Same stack; add uniformity metrics	Same axes	Surgical learning curve; comparability issues	Emerging modality
Photoreceptor precursors	Subretinal; precursor “Goldilocks” maturity	Requires synaptic integration; risk of material transfer illusion	Structural survival + layer targeting; function with integration-sensitive assays	Potency: Light-response surrogates + integration proxies	Disease stage; host residual photoreceptors	First-in-human transition; mechanism-of-benefit controversy
Immunology-as-engineering adjunct	Immunosuppression; scaffold immune barrier; hypoimmune iPSC	Enable durable allografts; must avoid immune escape	Safety surveillance; inflammation markers; imaging	Purity + proliferation markers; in vivo tumor surveillance	Immune privilege is relative	“Universal donor” direction but needs safeguards

CMC: Chemistry, manufacturing, and controls; RPE: Retinal pigment epithelium; OCT: Optical coherence tomography; FAF: Fundus autofluorescence; TEER: Transepithelial electrical resistance; PVR: Proliferative vitreoretinopathy; iPSC: Induced pluripotent stem cell.

Table 6 Two-tier, omics-enabled quality control framework linking multi-omics resources to Good Manufacturing Practice release criteria for retinal organoids and organoid-derived products

QC domain (CQA)	Essential for clinical translation?	Essential multi-omics criteria (process dev/periodic lot qualification)	Minimal routine GMP lot-release panel (examples; targeted assays)	Engineering → CMC translation output	Key evidence/precedent	Ref.
Identity & composition (intended lineage; correct cell-type stoichiometry)	Yes (CQA definition + re-qualification)	scRNA-seq cell-type composition; “composition envelope” across lots; reference-mapping to human retina atlas (maturity/trajectory score)	Targeted marker panel (flow/qPCR/IF): Lineage markers + subtype markers; morphology metrics where applicable	Converts atlas cell states into measurable CQAs; derives reduced marker sets; flags drift early	Retinal organoids vs adult retina single-cell reference; organoid heterogeneity quantified at scale	[143]
Purity/off-target tissues (non-retinal CNS, mesenchymal, RPE contamination etc.)	Yes	scRNA-seq off-target fraction; stress/reactive state detection (hypoxia/ISR/gliosis modules)	Release: Residual pluripotency (OCT4/TRA-1-60/NANOG) negative; proliferation (Ki67) limits; off-target marker negatives; viability & total cell number	Sets acceptance criteria for “allowed impurities”; links drift to process parameters (media/patterning/selection)	Organoid variability across systems supports need for systematic QC	[144]
Maturity/developmental congruence (photoreceptor/RPE functional readiness)	Yes for qualification; not per-lot mandatory	Reference mapping to fetal/adult retina trajectories; optional scATAC/multiome for competence state; optional spatial for lamination	Release: Maturity-linked targeted markers (e.g., phototransduction/synaptic readiness proxies) + predefined in-process timepoints	Defines “Goldilocks” maturity window; prevents under-/over-mature lots	HA conditioning improves photoreceptor maturation and uniformity (supports measurable maturation CQAs)	[110]
Potency (mechanism-linked biological activity)	Yes	Omics used to select potency mechanisms (pathway engagement signatures) and to justify assay choice; optional proteomics/metabolomics to connect transcript → function	Release: Validated potency assay(s) aligned to mechanism (e.g., RPE phagocytosis/TEER; photoreceptor light-response surrogates + integration-sensitive proxies)	Bridges omics biomarkers → potency assay design; supports assay justification	FDA potency guidance emphasizes mechanism-linked potency tests; lifecycle potency assurance	[145]
Safety/genetic stability (tumorigenicity risk, genome integrity)	Yes	Genomic characterization strategy (karyotype/CNV; WCB/MCB characterization); optional WGS where justified	Release: Sterility/mycoplasma/endotoxin; viability; residual pluripotency negative; proliferation limits; stability post-thaw	Links bank characterization to release and long-term follow-up	Cell substrate characterization expectations; ATMP quality requirements in trials	[146]
Comparability (manufacturing changes)	Yes when changes occur	Re-map lots with scRNA composition + maturity score; stress signature comparison; optional multiome/spatial if MoA-critical	Release: Same validated panel + bridging study endpoints	Provides quantitative “sameness” evidence after changes	FDA comparability guidance for CGT products	[162]

QC: Quality control; CQA: Critical quality attribute(s); scRNA-seq: Single-cell RNA sequencing; GMP: Good Manufacturing Practice; CMC: Chemistry, manufacturing, and controls; qPCR: Quantitative polymerase chain reaction; IF: Immunofluorescence; ISR: Integrated stress response; OCT4 Octamer-binding transcription factor 4 (POU5F1); TRA-1-60: Tumor rejection antigen 1-60; Ki67: Marker of cellular proliferation (Ki-67 antigen); CNS: Central nervous system; RPE: Retinal pigment epithelium; scATAC: Single-cell assay for transposase-accessible chromatin; HA: Hyaluronic acid; TEER: Transepithelial electrical resistance; FDA: Food and Drug Administration; CNV: Copy number variation; WCB: Working cell bank; MCB: Master cell bank; WGS: Whole-genome sequencing; ATMP: Advanced therapy medicinal product; CGT: Cell and gene therapy; MoA: Mechanism of action.